CA-125 vs. HE4: Why a Combined Approach May Be More Reliable
When it comes to ovarian health screening, understanding the difference between CA-125 and HE4 biomarkers — and why a combined approach may offer a more reliable picture — is increasingly important fo
When it comes to ovarian health screening, understanding the difference between CA-125 and HE4 biomarkers — and why a combined approach may offer a more reliable picture — is increasingly important for women taking a proactive role in their wellbeing. Neither marker alone tells the full story, and relying on a single result can sometimes lead to unnecessary concern or, conversely, false reassurance.
At Health Screening Clinic, our nurse-led team in London provides blood testing and reporting to help individuals gain clearer insight into their health. In this article, we explain what each biomarker measures, how they differ, and why combining CA-125 and HE4 is widely regarded as a more informative screening strategy.
What Are CA-125 and HE4? A Quick Definition
CA-125 (Cancer Antigen 125) is a protein biomarker found in the blood. Elevated levels can sometimes be associated with ovarian conditions, though levels may also rise due to benign causes such as endometriosis, fibroids, menstruation, or pelvic inflammatory disease.
HE4 (Human Epididymis Protein 4) is a newer biomarker that can also be measured through a simple blood test. HE4 tends to be more specific to certain ovarian changes and is less likely to be elevated by the common benign conditions that often affect CA-125 results.
Snippet Definition: CA-125 and HE4 are blood-based protein biomarkers used in ovarian health screening. When measured together, they may provide a more reliable assessment than either marker alone, helping to reduce both false positives and false negatives in the screening process.
Practical Insight: Understanding that each biomarker has its own strengths and limitations is the first step toward appreciating why a combined approach can be more meaningful.
How Do CA-125 and HE4 Differ?
While both biomarkers relate to ovarian health, they behave differently in the body and respond to different physiological conditions. The table below highlights the key differences:
| Feature | CA-125 | HE4 |
|---|---|---|
| Type | Glycoprotein biomarker | Protease inhibitor biomarker |
| Measured via | Blood test | Blood test |
| Specificity for ovarian concerns | Moderate — can be elevated by many benign conditions | Higher — less affected by common benign causes |
| Affected by menstruation | Yes | No |
| Affected by endometriosis | Yes — often significantly | Minimally |
| Affected by pregnancy | Yes | Minimally |
| Age-related variability | More variable in premenopausal women | More consistent across age groups |
| Use in ROMA score | Yes — combined with HE4 | Yes — combined with CA-125 |
| Availability in UK screening | Widely available | Increasingly available |
Practical Insight: For premenopausal women in particular, CA-125 alone can sometimes produce elevated readings that may not reflect genuine ovarian concerns. HE4 can help provide additional context in these situations.
Why May a Combined CA-125 and HE4 Approach Be More Reliable?
The concept behind combining these two biomarkers is straightforward: each marker compensates for the other’s limitations.
CA-125 has been used in clinical settings for decades and remains a valuable screening tool. However, its tendency to rise in response to various benign conditions — particularly in younger women — means that an elevated result does not always point to a significant concern. This can lead to what clinicians refer to as false positives, which may cause unnecessary worry.
HE4, on the other hand, is less reactive to common benign conditions but may not detect every ovarian change that CA-125 might highlight. Used alone, HE4 could potentially miss certain indicators that CA-125 would flag.
When both markers are assessed together, the combined data may:
- Reduce the rate of false-positive results compared to CA-125 alone
- Improve overall screening sensitivity by capturing a broader range of biomarker changes
- Support the calculation of the ROMA (Risk of Ovarian Malignancy Algorithm) score, which takes both markers plus menopausal status into account
- Offer a more balanced and nuanced picture of ovarian health
- Provide additional context for healthcare professionals reviewing results
This combined approach is increasingly referenced in UK clinical literature and is recognised by various international guidelines as a valuable tool in ovarian health assessment.
Practical Insight: A combined panel does not provide a diagnosis — it provides information. That information can then be discussed with an appropriate healthcare professional who can advise on any further steps if needed.
What Is the ROMA Score?
The ROMA (Risk of Ovarian Malignancy Algorithm) is a calculation that uses CA-125 levels, HE4 levels, and menopausal status to generate a risk stratification score. It is designed to help categorise individuals into lower or higher risk groups, which can then guide further clinical decision-making.
The ROMA score is not a diagnostic tool in itself. Rather, it may help healthcare professionals determine whether further investigation could be appropriate. It is one of several tools available in ovarian health assessment and is particularly noted for its ability to differentiate between benign and potentially more significant ovarian changes.
Practical Insight: If your results include a ROMA score, it is advisable to discuss the findings with a qualified healthcare professional who can interpret them within the context of your overall health history.
Who Should Consider CA-125 and HE4 Testing?
Ovarian health screening with a combined CA-125 and HE4 panel may be worth considering for:
- Women with a family history of ovarian or breast conditions
- Women over 50, particularly those who are postmenopausal
- Women experiencing persistent, unexplained symptoms such as bloating, pelvic discomfort, changes in appetite, or urinary frequency lasting more than a few weeks
- Women who carry known genetic factors (such as BRCA1 or BRCA2 variations) and wish to incorporate blood-based screening into their health monitoring
- Anyone seeking a broader overview of their wellbeing as part of a proactive health screening approach
It is important to note that screening is not the same as diagnosis. A blood test can highlight areas that may warrant further discussion with a healthcare professional, but it does not confirm or rule out any specific condition.
If you’re exploring options for women’s health blood tests, our clinic offers a range of panels designed to support proactive wellbeing monitoring.
How Often Should You Have CA-125 and HE4 Testing?
The frequency of ovarian biomarker testing can vary depending on individual circumstances. There is no single recommendation that applies to everyone.
As a general guide:
- For those with no specific risk factors, periodic screening as part of an annual or biannual health check may be appropriate.
- For those with a family history or known genetic factors, more frequent monitoring — potentially every 6 to 12 months — may be discussed with a healthcare professional.
- For those with previously elevated results, follow-up testing at intervals recommended by a qualified clinician can help track any changes over time.
Practical Insight: Establishing a baseline through initial testing can be particularly valuable. It allows future results to be compared against your own personal reference point, rather than relying solely on population-based reference ranges.
What Do Your Results Mean?
When you receive CA-125 and HE4 results, they will typically include reference ranges that indicate where your levels sit in relation to the general population.
- Results within the normal reference range generally suggest that no significant elevation has been detected at the time of testing.
- Mildly elevated results can sometimes reflect benign conditions, hormonal fluctuations, or other non-concerning factors. Context is essential.
- Significantly elevated results may indicate that further discussion with an appropriate healthcare professional is advisable.
Our clinic provides clear, detailed blood test reports that present your results alongside reference ranges and relevant context. We always recommend sharing your results with a qualified professional who can interpret them alongside your medical history and symptoms.
Accessing Combined Ovarian Biomarker Testing in London
For women in London and across the UK, access to combined CA-125 and HE4 blood testing has become more straightforward through private health screening services. While NHS pathways may involve waiting for a referral and meeting specific criteria, private testing allows individuals to take a proactive step on their own terms.
At Health Screening Clinic, we offer nurse-led blood testing in a comfortable, professional environment. Our role is to provide accurate testing and clear reporting — empowering you with information that can support informed conversations with your healthcare team.
For a broader view of the biomarkers and panels we offer, visit our full range of blood tests.
Frequently Asked Questions
1. What is the difference between CA-125 and HE4?
CA-125 and HE4 are both blood-based protein biomarkers associated with ovarian health. CA-125 can be elevated by many benign conditions, whereas HE4 tends to be more specific and less affected by common non-ovarian causes, making them complementary when used together.
2. Why may a combined CA-125 and HE4 approach be more reliable than CA-125 alone?
Combining CA-125 and HE4 may reduce false-positive results and improve overall screening accuracy. HE4 compensates for CA-125’s tendency to rise due to benign causes, while CA-125 can detect changes that HE4 alone might not flag.
3. What is the ROMA score and how is it calculated?
The ROMA score is a risk stratification algorithm that combines CA-125 levels, HE4 levels, and menopausal status. It helps categorise individuals into risk groups and may guide further clinical decision-making when interpreted by a healthcare professional.
4. Can CA-125 be elevated for reasons other than ovarian concerns?
Yes. CA-125 levels can sometimes rise due to endometriosis, fibroids, menstruation, pregnancy, pelvic inflammatory disease, and other benign conditions. This is one reason why a combined approach with HE4 may be more informative.
5. Who should consider a combined CA-125 and HE4 blood test?
Women with a family history of ovarian or breast conditions, those over 50, individuals with persistent unexplained symptoms, or anyone wishing to take a proactive approach to their health screening may find combined testing valuable.
6. How often should CA-125 and HE4 levels be checked?
Frequency depends on individual risk factors. Some individuals may benefit from annual screening, while those with higher risk profiles may discuss more frequent testing with their healthcare professional. Establishing a personal baseline is often a helpful starting point.
7. Can I get CA-125 and HE4 testing without a GP referral in the UK?
Yes. Private health screening clinics, such as Health Screening Clinic in London, offer CA-125 and HE4 blood testing without requiring a GP referral. This allows individuals to access screening on their own initiative.
8. What should I do if my CA-125 or HE4 results are elevated?
If your results show elevated levels, we recommend discussing the findings with an appropriate healthcare professional. Elevated results do not confirm a diagnosis — they indicate that further clinical assessment may be appropriate.
9. Is HE4 testing widely available in the UK?
HE4 testing is increasingly available through private health screening providers in the UK. While it may not always be included in standard NHS pathways, many private clinics now offer it as part of combined ovarian biomarker panels.
10. Does Health Screening Clinic provide diagnosis or treatment based on CA-125 and HE4 results?
No. Health Screening Clinic is a nurse-led service that provides blood testing and reporting only. We do not offer diagnosis, treatment, or prescriptions. We encourage all patients to share their results with a qualified healthcare professional for further guidance.
Our Commitment to Reliable, Evidence-Based Information
At Health Screening Clinic, every piece of content we publish is developed in line with UK medical editorial best practice. Our articles are informed by current clinical literature, written with an educational focus, and reviewed to ensure compliance with professional communication standards.
We believe that accessible, accurate health information empowers individuals to make informed decisions about their wellbeing. Our nurse-led team is committed to supporting proactive health monitoring through professional blood testing and clear, transparent reporting.
Take a Proactive Step for Your Wellbeing
If you’re considering ovarian biomarker screening, a combined CA-125 and HE4 blood test may provide a more comprehensive picture than either marker alone. The suitability of any screening test depends on individual clinical circumstances. Whether you have specific concerns or simply wish to stay informed about your health, our team is here to support you with professional, confidential testing in our London clinic.
Explore our available health screening options at www.healthscreeningclinic.co.uk or get in touch to learn more about how we can help. Please note that test availability and pricing may vary; full details will be provided prior to booking.